ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Takayasu arteritis"

  • Abstract Number: 1964 • 2019 ACR/ARP Annual Meeting

    A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)

    Anne Desbois1, Dragos Ciocan 2, David Saadoun 1, Gabriel Perlemuter 3 and Patrice Cacoub 4, 1GHPS, Paris, France, 2Hôpital Antoine Beclere, Clamart, France, 3Hôpital Clamart, Paris, France, 4AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

    Background/Purpose: The pathogenesis of Large Vessel Vasculitis (LVV) is not well understood. There is increasing evidence of a close link between intestinal dysbiosis and systemic…
  • Abstract Number: 2740 • 2019 ACR/ARP Annual Meeting

    Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex

    Xiufang Kong 1 and Amr Sawalha2, 1University of Michigan & Fudan University, Ann Arbor, MI, 2University of Pittsburgh & University of Michigan, Pittsburgh, PA

    Background/Purpose: Previous work has revealed a genetic association between Takayasu arteritis and a non-coding genetic variant in an enhancer region within IL6 (rs2069837 A/G). The…
  • Abstract Number: 2919 • 2019 ACR/ARP Annual Meeting

    Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

    Tomoyuki Mutoh1, Tsuyoshi Shirai 1, Tomonori Ishii 2, Yuko Shirota 3, Hideo Harigae 1 and Hiroshi Fujii 1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Tohoku University Hospital, Sendai, Japan, 3Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan

    Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in…
  • Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting

    Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis

    K Bates Gribbons1, Cristina Ponte 2, Anthea Craven 3, David Cuthbertson 4, Simon Carette 5, Gary S. Hoffman 6, Nader A. Khalidi 7, Curry L. Koening 8, Carol Langford 9, Kathleen Maksimowicz-McKinnon 10, Carol A. McAlear 11, Paul Monach 12, Larry Moreland 13, Christian Pagnoux 14, Kaitlin Quinn 15, Joanna Robson 16, Philip Seo 17, Antoine Sreih 18, Ravi Suppiah 19, Kenneth Warrington 20, Steven Ytterberg 21, Raashid Luqmani 3, Richard Watts 22, Peter Merkel 18 and Peter C. Grayson 23, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, 3University of Oxford, Oxford, United Kingdom, 4University of South Florida, Tampa, FL, 5Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 6Cleveland Clinic Foundation, Cleveland, OH, 7McMaster University, Hamilton, ON, Canada, 8University of Utah Hospital, Salt Lake City, UT, 9Cleveland Clinic, Cleveland, OH, 10Henry Ford Hospital, Wayne State University, Detroit, MI, 11University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 12Brigham and Women's Hospital, Boston, MA, 13University of Pittsburgh, PITTSBURGH, PA, 14Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 15Georgetown University Hospital/National Institutes of Health, Washington, DC, 16Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 17Johns Hopkins Medicine, Baltimore, MD, 18University of Pennsylvania, Philadelphia, PA, 19Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 20Mayo Clinic Rochester, Rochester, MN, 21Mayo Clinic College of Medicine, Rochester, MN, 22Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 23National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…
  • Abstract Number: 779 • 2017 ACR/ARHP Annual Meeting

    Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)

    Shubhasree Banerjee1, Sara Alehashemi2, Ali Cahid Civelek3, Elaine Novakovich4, Armin Bagheri5, Ashkan Malayeri3, Mark Ahlman3 and Peter C. Grayson6, 1Fellowship and training branch, NIAMS/NIH, Bethesda, MD, 2Rheumatology, National Institutes of Health, Bethesda, MD, 3Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 4Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, 5Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, 6Research, National Institutes of Health, Bethesda, MD

    Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serological (ESR, CRP) parameters. Imaging assessment, including FDG-PET, may also be…
  • Abstract Number: 901 • 2016 ACR/ARHP Annual Meeting

    Clinical Features of  Takayasu’s Arteritis from an Inception Cohort: Early Disease Is Characterized By ‘systemic Inflammation’

    Fatma Alibaz-Oner1, Ali Ugur Unal2, Ahmet Mesut Onat3, Bunyamin Kisacik4, Orhan Zengin5, Omer Karadag6, Abdulsamet Erden6, Handan Yarkan7, Servet Akar8, Fatih Yildiz9, Eren Erken10, Huseyin Özer11, Ahmet Omma12, Zeynep Ozbalkan13, Yasar Karaaslan14, Cemal Bes15, Sibel Yilmaz Oner15, Nilufer Alpay Kanitez15, Ozun Bayndır16, Sule Yavuz17, Nursen Duzgun18, Ayse Nur Tufan19, Ediz Dalkilic19, Hajime Yoshifuji20, Abdurrahman Tufan17, Lutfi Akyol21, Mehmet Akif Ozturk22, Mehmet Sayarlioglu23, Kenan Aksu16, Gokhan Keser24, Sedat Kiraz25, Omer Nuri Pamuk26, Fatos Onen27 and Haner Direskeneli28, 1Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 3Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, 4Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, 5Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 6Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 7Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 8Department of Rheumatology, İzmir Katip Çelebi University, School of Medicine, İzmir, Turkey, İzmir, Turkey, 9Rheumatology, Van EAH, Adana, Turkey, 10Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, 11Rheumatology, Cukurova Univesity, School of Medicine, Adana, Turkey, 12Department of Internal Medicine, Rheumatology Division, Ankara Numune Hospital, Ankara, Turkey, 13Rheumatology Departent, MD,Assoc. Prof., Ankara, Turkey, 14Rheumatology, Turkish Takayasu's Arteritis Study Group, Istanbul, Turkey, 15Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 16İnternal Medicine Division of Rheumatology, Ege University Medical Faculty, Izmir, Turkey, 17PsART study group, Ankara, Turkey, 18Internal Medicines, Rheumatology Department, Ankara University School of Medicine, Ankara, Turkey, 19Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, 20Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 21Department of Internal Medicine Division of Rheumatology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey, 22Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 23Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, 24Rheumatology, Ege University Medical Faculty, Izmir, Turkey, 25Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, 26Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, 27Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 28Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose:  There is only retrospective and very limited data for the long term prognosis of Takayasu's Arteritis (TAK), a rare large-vessel vasculitis. In this study,…
  • Abstract Number: 979 • 2016 ACR/ARHP Annual Meeting

    A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Takayasu’s Arteritis

    Carol A. Langford1, David Cuthbertson2, Steven R. Ytterberg3, Nader A. Khalidi4, Paul A. Monach5, Simon Carette6, Philip Seo7, Larry W. Moreland8, Michael Weisman9, Curry L. Koening10, Antoine G. Sreih11, Robert F. Spiera12, Carol A McAlear13, Kenneth J. Warrington3, Christian Pagnoux14, Kathleen Maksimowicz-McKinnon15, Lindsy J. Forbess9, Gary S. Hoffman16, Renee Borchin17, Jeffrey Krischer17 and Peter A. Merkel18, 1Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 2Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 3Rheumatology, Mayo Clinic, Rochester, MN, 4McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5Rheumatology, Boston University School of Medicine, Boston, MA, 6Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 8Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 10Rheumatology, University of Utah, Salt Lake City, UT, 11Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, 12Hospital for Special Surgery, Cornell, New York, NY, 13Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 14Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 15Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 16Rheumatology, Cleveland Clinic, Cleveland, OH, 17University of South Florida, Tampa, FL, 18Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Takayasu’s arteritis (TAK) is a large-vessel primary systemic vasculitis that affects the aorta, its branches, and the pulmonary arteries. Despite treatment with glucocorticoids, relapse…
  • Abstract Number: 1287 • 2016 ACR/ARHP Annual Meeting

    Utility of Vascular Findings By PET/CT Scan in the Diagnosis and Activity Assesment of Takayasu Arteritis

    Bahtiyar Toz1, Zeynep Gözde Özkan2, Bahar Artim-Esen1, Burak Erer1, Sevil Kamali3, Ahmet Gul1, Lale Ocal3 and Murat Inanc4, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Nuclear Medicine,, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, 3Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey

    Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis predominantly affecting the aorta and its main branches. Assessing disease activity is difficult and mainly based on…
  • Abstract Number: 3062 • 2015 ACR/ARHP Annual Meeting

    Frequency, Presentation and Outcome of Takayasu Arteritis in Western Australia

    Krista Makin1, Maxine Garnsey2 and Johannes Nossent3, 1Rheumatology, Fiona Stanley Hospital, Murdoch, Australia, 2Internal Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 3Medicine, University of Western Australia, WA, Australia

    Background/Purpose: Takayasu Arteritis (TAK) is a systemic large-vessel vasculitis that mostly affects women of childbearing age. The worldwide incidence of TAK varies due to genetic…
  • Abstract Number: 3067 • 2015 ACR/ARHP Annual Meeting

    Microscopic Colitis in Patients with Takayasu Arteritis; A Potential Association Between the Two Disease Entities

    Nilufer Alpay Kanitez1, Bahtiyar Toz1, Mine Gulluoglu2, Burak Erer1,3, Murat Inanc4, Bilger Cavus5, Raim Iliaz5, Cetin Karaca5 and Sevil Kamali1, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Pathology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, 3Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, 5Department of Internal Medicine, Division of Gastroenterology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey

    Background/Purpose: Takayasu's arteritis (TAK) is a chronic vasculitis of large-vessels, mainly affects the aorta and its branches in the middle-aged females. There are reports regarding…
  • Abstract Number: 810 • 2014 ACR/ARHP Annual Meeting

    Damage Assessment in Takyasu Arteritis Using Takayasu Arteritis Damage Score (TADS)

    Debashish Danda1, Ruchika Goel2, Raheesh Ravindran2 and George Joseph3, 1Clinical Immunology& Rheum, Christian Medical College, Vellore Tamilnadu, India, 2Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India, Vellore, India, 3Cardiology, Christian Medical College & Hospital, Vellore, India, Vellore, India

    Background/Purpose Takayasu arteritis (TA) is a prototype large vessel vasculitis. Assessment of disease activity and damage has been challenging in TA due to lack of…
  • Abstract Number: 801 • 2014 ACR/ARHP Annual Meeting

    Venothromboembolism in Large Vessel Vasculitis

    Sankalp V. Bhavsar1, Nader A. Khalidi2, Simon Carette3, David Cuthbertson4, Peter C. Grayson5, Gary S. Hoffman6, Curry L. Koening7, Carol A. Langford8, Carol McAlear9, Larry Moreland10, Paul A. Monach11, Christian Pagnoux3, Philip Seo12, Kenneth J. Warrington13, Steven R. Ytterberg13 and Peter A. Merkel14, 1Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 2Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 4Department of Biostatistics, University of South Florida, Tampa, FL, 5NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, 6Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 7Division of Rheumatology, University of Utah, Salt Lake City, UT, 8Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 9Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 10Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, 11Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, 12Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 13Division of Rheumatology, Mayo Clinic, Rochester, MN, 14University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Venous thromboembolic disease (VTE) is a recognized characteristic of various systemic vasculitides, particularly small-vessel vasculitis.  However, there are no reports describing the frequency of…
  • Abstract Number: 1686 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab In Refractory Takayasu Arteritis:  a Case Series and Updated Literature Review.²

    Noemie Abisror1, Arsene Mekinian2, Christian Lavigne3, Marie Anne Vandenhende4, Michael Soussan5 and Olivier Fain1, 1Internal Medicine, Jean Verdier Hospital, Bondy, France, 2Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, 3Internal Medicine, Angers, France, 4Internal Medicine, Bordeaux, France, 5Nuclear Medicine, Avicennes Hospital, Bobigny, France

    Tocilizumab in refractory Takayasu arteritis:  a case series and updated literature review.Background/Purpose: The aim of this study is to analyze the efficacy and tolerance of…
  • Abstract Number: 1681 • 2013 ACR/ARHP Annual Meeting

    Assessment of Patients With Takayasu’s Arteritis in Routine Clinical Follow-Up With Indian Takayasu Clinical Activity Score 2010(ITAS2010)

    Fatma Alibaz-Oner and Haner Direskeneli, Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: ITAS2010 (Indian Takayasu Clinical Activity Score) is a new composite index developed to assess clinical activity in Takayasu’s arteritis (TAK), which is weighted for…
  • Abstract Number: 1680 • 2013 ACR/ARHP Annual Meeting

    Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?

    Ahmet Omma1, Burak Erer2, Nilufer Alpay3, Nuray Gurel Polat4, Ahmet Gul1, Murat Inanc4, Lale Ocal1 and Sevil Kamali1, 1Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Rheumatology Division, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 3Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: Takayasu arteritis (TA) is a chronic vasculitis with an indolent course. Reliable diagnostic and activity markers have not yet been demonstrated. We aimed to…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology